| All Releases |
|---|
 |
Progenics Announces Positive Top-Line Results from Second Pivotal Phase 3 Clinical Trial of Methylnaltrexone in Opioid-Induced Constipation; All Primary and Secondary Efficacy Endpoints Were Highly Statistically Significant
Feb 15, 2006
|
84.5 KB
|
| |
TARRYTOWN, N.Y.--(BUSINESS WIRE)--Feb. 15, 2006--
Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced
positive top-line results from the second pivotal phase 3 clinical
trial of methylnaltrexone (MNTX) for the treatment of opioid-induced
constipation in patients with advanced medical illness. MNTX is a
peripheral opioid receptor...
|
|
| |
Wyeth and Progenics Pharmaceuticals Announce Worldwide Collaboration to Develop and Commercialize Methylnaltrexone
Dec 23, 2005
|
64.8 KB
|
| |
Progenics Acquires Methylnaltrexone Rights from Licensors and Plans to File Shelf Registrations
Dec 23, 2005
|
33.5 KB
|
| |
Progenics Pharmaceuticals Initiates Clinical Trial of Viral-Entry Inhibitor PRO 140 in HIV-Infected Patients
Dec 1, 2005
|
29.2 KB
|
| |
Progenics Pharmaceuticals Reports Third Quarter 2005 Results
Nov 7, 2005
|
105.5 KB
|
| |
Progenics and Cytogen Report Potent Anti-Tumor Activity for Experimental Prostate Cancer Drug
Sep 30, 2005
|
45.6 KB
|
| |
Progenics Achieves Enrollment Target in Second Pivotal Phase 3 Clinical Trial of Methylnaltrexone for Opioid-Induced Constipation
Sep 30, 2005
|
35.6 KB
|
| |
Progenics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Sep 14, 2005
|
24.3 KB
|
| |
Progenics Reports Positive Results from Phase I Clinical Trial of PRO 140, a Novel Monoclonal Antibody That Blocks HIV Entry
Sep 9, 2005
|
44.7 KB
|
| |
Progenics Reports Additional Positive Resultsfrom Methylnaltrextone Phase 3 Clinical Trial
Aug 22, 2005
|
41.6 KB
|
| |
Progenics Pharmaceuticals Reports Second Quarter 2005 Results
Aug 9, 2005
|
42.1 KB
|
| |
Progenics Completes Enrollment in Phase 1 Clinical Trial of PRO 140, a Novel HIV Entry Inhibitor Targeting CCR5
Jul 26, 2005
|
42.1 KB
|
| |
Progenics Announces Management Team Expansion and Promotion
Jun 29, 2005
|
26.2 KB
|
| |
Progenics Pharmaceuticals Announces Pricing of Public Offering of Common Stock; Offering Made Pursuant to Previously Filed "Shelf" Registration Statement
Jun 10, 2005
|
20.0 KB
|
| |
Progenics Pharmaceuticals Added to NASDAQ Biotechnology Index
May 16, 2005
|
23.3 KB
|
| |
Progenics Pharmaceuticals Reports First Quarter 2005 Results
May 10, 2005
|
22.5 KB
|
| |
Progenics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Apr 1, 2005
|
24.2 KB
|
| |
Progenics Pharmaceuticals Reports Fourth Quarter and Year End Results
Mar 16, 2005
|
67.2 KB
|
| |
Progenics Announces Management Changes
Mar 10, 2005
|
40.8 KB
|
| |
Progenics Announces Positive Top-Line Results from Pivotal Phase 3 Clinical Trial Of MNTX in Opioid-Induced Constipation
Mar 10, 2005
|
54.3 KB
|
|
